Targeting chimera technology: A new tool for undruggable in breast cancer.
10.11817/j.issn.1672-7347.2025.250032
- Author:
Zhongwu CHEN
1
,
2
,
3
;
Sandi SHEN
1
;
Xiaoyu SONG
4
;
Bin XIAO
3
,
5
Author Information
1. Department of Breast Surgery, Affiliated Qingyuan Hospital (Qingyuan People's Hospital), Guangzhou Medical University, Qingyuan
2. chenzhongwu12@
3. com.
4. Central Laboratory, Affiliated Panyu Central Hospital of Guangzhou Medical University, Guangzhou
5. Department of Laboratory Medicine, Southern Medical University Hospital of Integrated Traditional Chinese and Western Medicine, Guangzhou 510315, China. xiaobin2518@
- Publication Type:English Abstract
- Keywords:
breast cancer;
proteolysis targeting chimeras;
ribonuclease targeting chimeras;
targeting chimera technology;
undruggable targets
- MeSH:
Humans;
Breast Neoplasms/drug therapy*;
Female;
Proteolysis;
Ribonucleases/metabolism*;
Molecular Targeted Therapy/methods*;
Antineoplastic Agents/therapeutic use*
- From:
Journal of Central South University(Medical Sciences)
2025;50(7):1244-1254
- CountryChina
- Language:Chinese
-
Abstract:
Breast cancer is one of the most common and fatal malignancies among women worldwide, and its treatment efficacy is often limited by drug resistance and the presence of undruggable targets. Traditional small-molecule drugs have difficulty effectively modulating certain critical targets such as transcription factors and non-coding RNAs, necessitating new therapeutic strategies. Proteolysis-targeting chimeras (PROTACs) function by recruiting pathogenic proteins to the cellular ubiquitin-proteasome system, thereby inducing their specific degradation. In contrast, ribonuclease-targeting chimeras (RIBOTACs) utilize small-molecule ligands but bind to RNA and direct endogenous RNases to selectively degrade pathogenic RNA molecules. By employing a "degradation rather than inhibition" mechanism, targeting chimera technology broadens the druggable landscape and offers a novel precision therapeutic strategy for breast cancer, particularly for refractory and drug-resistant cases. This approach not only overcomes the limitations of traditional drugs, such as the absence of suitable binding sites or poor selectivity, but also reduces required dosages and potential adverse effects. Recent studies have preliminarily demonstrated the therapeutic potential of PROTACs and RIBOTACs in breast cancer, encompassing target design, mechanistic investigation, and preclinical as well as early clinical applications. Research into these technologies reveals their ability to tackle previously undruggable targets, thereby providing theoretical support for the development of safer and more effective precision therapies for breast cancer. In the future, with advances in drug delivery systems and clinical trials, PROTACs and RIBOTACs are expected to be used synergistically with immunotherapy and chemotherapy, offering breast cancer patients more promising comprehensive treatment options and potentially driving oncology toward broader intervention of undruggable targets.
